Nurix Therapeutics
Quarterly Financials
| Values in thousands | 2025-02-28 | 2024-11-30 | 2024-08-31 | 2024-05-31 |
|---|---|---|---|---|
Revenue | $18,453 | $13,284 | $12,588 | $12,092 |
Gross Profit | 18,453 | 13,284 | 8,442 | 8,001 |
EBITDA | -62,864 | -60,354 | -50,465 | -44,449 |
EBIT | -64,657 | -54,611 | -48,540 | |
Net Income | -56,351 | -58,549 | -48,956 | -44,546 |
Net Change In Cash | 18,453 | 13,284 | 12,588 | 12,092 |
Free Cash Flow | -64,572 | -50,856 | -44,524 | -41,642 |
Cash | 75,916 | 109,997 | 99,044 | 116,790 |
Basic Shares | 83,560 | 78,410 | 72,779 | 62,377 |
Annual Financials
| Values in thousands | 2024-11-30 | 2023-11-30 | 2022-11-30 | 2021-11-30 |
|---|---|---|---|---|
Revenue | $54,549 | $76,987 | $38,627 | $29,750 |
Gross Profit | 54,549 | -112,161 | 38,627 | 29,750 |
EBITDA | -213,027 | -141,409 | -173,059 | -111,804 |
EBIT | -155,063 | -183,867 | -117,886 | |
Net Income | -193,569 | -143,948 | -166,045 | -117,194 |
Net Change In Cash | 54,549 | 76,987 | 38,627 | 29,750 |
Cost of Revenue | -15,417 | -38,734 | ||
Free Cash Flow | -181,857 | -89,766 | -172,051 | -90,026 |
Cash | 109,997 | 54,627 | 64,474 | 80,506 |
Basic Shares | 67,120 | 54,337 | 48,607 | 42,895 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-02-28 | -$0.67 |
2024-11-30 | -$0.75 |
2024-08-31 | -$0.67 |
2024-05-31 | -$0.71 |
